Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Cymbalta Clears FDA For Diabetes-Related Neuropathic Pain After Priority Review

This article was originally published in The Pink Sheet Daily

Executive Summary

Sales reps will start promoting the neuropathic pain indication to neurologists and pain specialists in the fourth quarter. After Lilly is confident duloxetine has been appropriately positioned as an antidepressant, a more active marketing of the neuropathic pain indication to primary care physicians will begin.

You may also be interested in...



Lilly’s Cymbalta Gets Generalized Anxiety Disorder Indication

Lilly continues to evaluate the “marketing mix” for the serotonin-norepinephrine reuptake inhibitor, firm tells “The Pink Sheet” DAILY.

Lilly’s Cymbalta Gets Generalized Anxiety Disorder Indication

Lilly continues to evaluate the “marketing mix” for the serotonin-norepinephrine reuptake inhibitor, firm tells “The Pink Sheet” DAILY.

DOV Out-Licenses Pain Candidate Bicifadine To XTL

XTL shifts bicifadine’s development away from “novel indications in acute and chronic pain” to neuropathic pain, firm says.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel